Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis

ClinicalTrials.gov ID: NCT01516918

Public ClinicalTrials.gov record NCT01516918. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 3:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Open-Label Phase 2b Pilot Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir, Peginterferon-Alfa-2, and Ribavirin) in Subjects With Genotype 1 Chronic Hepatitis C With Compensated Cirrhosis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the safety and efficacy of a quadruple regimen (VX-222, telaprevir, pegylated interferon, and ribavirin)in subjects with hepatitis C with cirrhosis.

Study identification

NCT ID
NCT01516918
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Enrollment
103 participants

Conditions and interventions

Interventions

Drug · Biological

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2012
Primary completion
Aug 31, 2013
Completion
Nov 30, 2013
Last update posted
Oct 19, 2014

2012 – 2013

United States locations

U.S. sites
28
U.S. states
19
U.S. cities
28
Facility City State ZIP Site status
Not listed Birmingham Alabama
Not listed San Diego California
Not listed Englewood Colorado
Not listed Bradenton Florida
Not listed Jacksonville Florida
Not listed Tampa Florida
Not listed Marietta Georgia
Not listed Chicago Illinois
Not listed Indianapolis Indiana
Not listed Boston Massachusetts
Not listed Detroit Michigan
Not listed Lebanon New Hampshire
Not listed Egg Harbor New Jersey
Not listed Manhasset New York
Not listed New York New York
Not listed Rochester New York
Not listed Asheville North Carolina
Not listed Charlotte North Carolina
Not listed Durham North Carolina
Not listed Cincinnati Ohio
Not listed Providence Rhode Island
Not listed Germantown Tennessee
Not listed Arlington Texas
Not listed Houston Texas
Not listed San Antonio Texas
Not listed Norfolk Virginia
Not listed Madison Wisconsin
Not listed Milwaukee Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01516918, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 19, 2014 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01516918 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →